Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Mar 15:15:1181-1193.
doi: 10.2147/DDDT.S297918. eCollection 2021.

Pharmacokinetics, Bioequivalence and Safety Evaluation of Two Ticagrelor Tablets Under Fasting and Fed Conditions in Healthy Chinese Subjects

Jin Wang #  1 , Huan Zhang #  1 , Rui Wang  1 , Yun Cai  1
Affiliations
Randomized Controlled Trial

Pharmacokinetics, Bioequivalence and Safety Evaluation of Two Ticagrelor Tablets Under Fasting and Fed Conditions in Healthy Chinese Subjects

Jin Wang et al. Drug Des Devel Ther. .

Abstract

Purpose: To evaluate the pharmacokinetics (PK), bioequivalence and safety profiles of test drug and reference drug of 90 mg ticagrelor tablets and their main active metabolite AR-C124910XX under fasting and fed conditions.

Methods: This was a randomized, open-label, single-dose, two-period, two-sequence, and two-treatment crossover study. Subjects were randomized and evenly administered with a single dose of test drug or reference drug of 90 mg ticagrelor tablets orally under fasting or fed conditions with a 7-day washout period. The primary PK parameters were calculated with non-compartmental model, including peak concentration (Cmax), area under the curve (AUC) from zero to last quantifiable concentration (AUC0-t), and AUC from zero to infinity (AUC0-∞). Bioequivalence was judged by whether the 90% confidence intervals (CIs) of the geometric mean ratio (GMR) of the test/reference drugs were within the predefined range of 80-125%. Adverse events (AEs) were assessed as safety endpoints.

Results: Eighty healthy Chinese subjects (fasting condition: n=40; fed condition: n=40) were enrolled, but two withdrew for personal reasons. As for PK parameters, there was no statistical difference (P>0.05) between the test and reference drugs under both conditions. As for bioequivalence, the 90% CIs of GMR for Cmax, AUC0-t and AUC0-∞ all fell within 80%-125% regardless of food intake or not. No severe adverse events were observed in the study. Chinese clinical trial registration number is ChiCTR1800015091 (http://www.chictr.org.cn).

Conclusion: Our results demonstrated that the test drug and the reference drug of ticagrelor tablets were bioequivalent. The PK and safety profiles were also similar regardless of food intake or not in healthy Chinese subjects.

Keywords: bioequivalence; pharmacokinetics; safety; ticagrelor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1
The study flow chart under fasting and fed conditions.
Figure 2
Figure 2
Mean plasma concentration–time curves of ticagrelor under fasting condition – Pharmacokinetic Analysis Concentration Set (PKCS).
Figure 3
Figure 3
Mean plasma concentration–time curves of ticagrelor under fed condition – Pharmacokinetic Analysis Concentration Set (PKCS).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Smith JN, Negrelli JM, Manek MB, Hawes EM, Viera AJ. Diagnosis and management of acute coronary syndrome: an evidence-based update. J Am Board Fam Med. 2015;28(2):283–93. doi:10.3122/jabfm.2015.02.140189 - DOI - PubMed
    1. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596. - PubMed
    1. Tersalvi G, Biasco L, Cioffi GM, Pedrazzini G. Acute coronary syndrome, antiplatelet therapy, and bleeding: a clinical perspective. J Clin Med. 2020;9(7):2064. doi:10.3390/jcm9072064 - DOI - PMC - PubMed
    1. Al-Salama ZT, Keating GM, Keam SJ. Ticagrelor: a review in long term secondary prevention of cardiovascular events. Drugs. 2017;77(18):2025–2036. doi:10.1007/s40265-017-0844-8 - DOI - PubMed
    1. Dobesh PP, Finks SW, Trujillo TC. Dual antiplatelet therapy for long-term secondary prevention of atherosclerotic cardiovascular events. Clin Ther. 2020;42(10):2084–2097. doi:10.1016/j.clinthera.2020.08.003 - DOI - PubMed

Publication types